News

Apply Now for the Shauna M. Sorrells Program

In 2020, G2G Consulting launched the Shauna M. Sorrells Program to provide a $10,000 grant to a nonprofit that dedicates meaningful services and programs to women and children, especially women of color.

Award winners have provided programming in breast cancer screening services, maternal health, housing, STEM education programs, adult literacy, domestic violence shelter, and career advancement services.

⮕ How it Works:

Grants are for small nonprofits providing services to women and children and communities of color. All applicants must be a nonprofit with an annual budget of $3 million or less. Preference is granted to organizations serving women and children, especially people of color. If you have been awarded grants twice before, you are not eligible for funding. Once three finalists are selected, the voting begins to select the Grand Prize Winner.

Applications are open October 1 – 27.

 

Apply Now

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business